Down syndrome-associated leukaemias: current evidence and challenges

Area of Science:

• Hematology
• Genetics
• Pediatric Oncology

Background:

• Children with Down syndrome (DS) exhibit an elevated risk for hematological malignancies, specifically acute megakaryoblastic leukemia and acute lymphoblastic leukemia.
• Leukemogenesis in DS is influenced by trisomy 21-driven abnormal hematopoiesis, further driven by genetic and epigenetic alterations.
• Somatic mutations in GATA-binding protein 1 (GATA1) are pivotal in transient abnormal myelopoiesis and the progression to myeloid leukemia of DS (ML-DS).

Purpose of the Study:

• To review the primary genetic drivers contributing to leukemia development in individuals with Down syndrome.
• To summarize the biology and current treatment strategies for ML-DS and DS-associated acute lymphoblastic leukemia.
• To discuss the long-term effects of leukemia treatments in DS patients and outline future targeted therapy directions.

Main Methods:

• Literature review focusing on genetic drivers of leukemia in Down syndrome.
• Synthesis of information on the biology and treatment of ML-DS and DS-associated ALL.
• Analysis of late treatment effects and future therapeutic targets.

Main Results:

• Identified key genetic factors, including GATA1 mutations, that drive leukemogenesis in DS.
• Detailed the biological pathways and therapeutic approaches for ML-DS and DS-associated ALL.
• Highlighted significant late effects of treatments and emerging targeted therapies.

Conclusions:

• Genetic alterations, particularly GATA1 mutations, are central to leukemia development in Down syndrome.
• Understanding the biology of DS-leukemias is crucial for effective treatment and management of late effects.
• Future research should focus on targeted therapies to improve outcomes for children with Down syndrome and leukemia.